JFS Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

JFS Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-782	Closed	-$53.3K	–	2001
2024 Q1	$53.3K	Buy	+782	New	+$56K	﹤0.01%	416
2021 Q4	–	Sell	-90	Closed	-$10K	–	1745
2021 Q3	$10K	Buy	+90	New	+$11.3K	﹤0.01%	634

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

JFS Wealth Advisors's CRSP Position: Q2 2024 in Review

JFS Wealth Advisors sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 782 shares — an estimated $53.3K sold.

JFS Wealth Advisors first reported a position in CRSP in Q3 2021 and held it in 2 quarters. The position peaked at $53.3K in Q1 2024. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

JFS Wealth Advisors reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
JFS Wealth Advisors sold 782 CRISPR Therapeutics shares in Q2 2024, an estimated $53.3K.
JFS Wealth Advisors first reported a position in CRISPR Therapeutics in Q3 2021 and held it in 2 quarters.
JFS Wealth Advisors's CRISPR Therapeutics position peaked at $53.3K in Q1 2024.
449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on JFS Wealth Advisors's 13F filing for Q2 2024, filed 15 Jul 2024.